Thelansis

  Non–small cell lung cancer (NSCLC) is the most common form of lung cancer. Early-stage NSCLC accounts for approximately 18% of the cases. Most patients are treated with curative intent and often require multimodality therapy. The 5-year overall survival (OS) ranges from 50% for stage IA disease to 15% for stage IIIA NSCLC. Several clinical trials have demonstrated improved survival with postoperative chemotherapy in selected patients who undergo complete surgical resection. Available evidence supports the use of adjuvant chemotherapy for stage II and stages IIIA but not for stage IA NSCLC. The standard of care for patients with stage I and II and IIIA, non-small-cell lung cancer (NSCLC), is surgical resection. Following resection, patients may be offered adjuvant systemic therapy. HER2 mutations and HER2 amplifications have been reported in approximately 2% to 3% and 2% to 5% of lung adenocarcinomas, respectively. Thelansis’s “Non–Small Cell Lung Cancer (NSCLC) Ma...